Rafael Holdings, Inc. Cash Flow Conversion Efficiency
Rafael Holdings, Inc. cash flow conversion efficiency. Based on the latest financial reports, Rafael Holdings, Inc. (RFL) has a cash flow conversion efficiency ratio of -0.090x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.51 Million) by net assets ($83.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Rafael Holdings, Inc. (2016–2025)
Cash flow conversion efficiency of Rafael Holdings, Inc. from 2016 to 2025. This chart illustrates how Rafael Holdings, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View RFL live share price for real-time trading data and today's change.
Rafael Holdings, Inc. Cash Flow Conversion Ratio Explained
Rafael Holdings, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Rafael Holdings, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rafael Holdings, Inc. ranked by their cash flow conversion efficiency. Also see RFL market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fanhua Inc.
NASDAQ:AIFU
|
0.117x |
|
Melhus Sparebank
OL:MELG
|
0.110x |
|
Biome Australia Ltd
AU:BIO
|
0.344x |
|
Dutaland Bhd
KLSE:3948
|
-0.019x |
|
Centrepoint Alliance Ltd
AU:CAF
|
0.085x |
|
Envoy Medical Inc.
NASDAQ:COCH
|
-1.652x |
|
Traphaco JSC
VN:TRA
|
0.017x |
|
Decibel Cannabis Company Inc
V:DB
|
0.028x |
Annual Cash Flow Conversion Efficiency for Rafael Holdings, Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Rafael Holdings, Inc. from 2016 to 2025. Review RFL cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-07-31 | $98.37 Million | $-18.92 Million | -0.192x | -112.69% |
| 2024-07-31 | $86.26 Million | $-7.80 Million | -0.090x | +19.71% |
| 2023-07-31 | $96.63 Million | $-10.89 Million | -0.113x | +58.01% |
| 2022-07-31 | $97.21 Million | $-26.08 Million | -0.268x | -135.09% |
| 2021-07-31 | $136.70 Million | $-15.60 Million | -0.114x | -219.25% |
| 2020-07-31 | $130.53 Million | $-4.67 Million | -0.036x | -42.40% |
| 2019-07-31 | $124.76 Million | $-3.13 Million | -0.025x | -59.84% |
| 2018-07-31 | $115.56 Million | $-1.81 Million | -0.016x | +39.93% |
| 2017-07-31 | $62.08 Million | $-1.62 Million | -0.026x | -1872.49% |
| 2016-07-31 | $48.81 Million | $72.00K | 0.001x | -- |
About Rafael Holdings, Inc.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells… Read more